BioCentury | Jul 24, 2020
Politics, Policy & Law

Moderna says commercial path remains clear despite unfavorable patent ruling

Moderna isn’t aware of any IP barriers to its products, including its COVID-19 vaccine, after a PTAB decision on Thursday shaved more than $3 billion off its market cap. The Patent Trial and Appeal Board...
BioCentury | Mar 19, 2020
Product Development

Roivant pivots towards ARDS in COVID-19; plus Italian studies of repurposed anti-inflammatories, vaccine updates and more

Wednesday saw a full slate of clinical updates across the globe for vaccine and therapeutic candidates to address COVID-19, while HHS launched a new public-private partnership to ramp up emergency drug packaging capabilities. Roivant Sciences...
BC Extra | Jan 25, 2020
Company News

Management tracks: Galapagos promotes Manto to CCO; plus Guardant, Horizon, Acceleron, Lilly, Krystal, Kura and more

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) promoted Michele Manto to chief commercial officer from SVP, commercial operations. Before joining the inflammation and fibrosis company in 2017, he was general manager, global marketing rheumatology at AbbVie Inc. (NYSE:ABBV)....
BC Extra | Jan 16, 2020
Company News

Jan. 15 Company Quick Takes: Japan Tobacco gets rights to Dermavant therapy; plus Clovis, BMS, Recordati, BeiGene, Insilico-Pfizer, Novartis

Japan Tobacco gets Japanese rights to Dermavant’s dermatology therapy  Japan Tobacco Inc. (TOKYO:2914) licensed from Dermavant Sciences exclusive rights to develop and commercialize tapinarof in Japan for dermatology indications including psoriasis and atopic dermatitis. The...
BC Extra | Nov 19, 2019
Clinical News

Big gain for Myovant as oral prostate cancer therapy heads for submission

Myovant shares more than doubled in value Tuesday after the company revealed Phase III data showing its oral GnRH receptor antagonist relugolix led to sustained testosterone suppression in 96.7% of prostate cancer patients in Phase...
BC Extra | Oct 31, 2019
Company News

Roivant pockets $3B from Dainippon, reveals CF focus of fifth ‘vant’

As Roivant cements its deal for Dainippon to acquire five of its “vants” for $3 billion, the biotech revealed the identity of the deal’s fifth subsidiary, which will develop gene therapies for cystic fibrosis. Sumitomo...
BC Extra | Oct 3, 2019
Company News

Oct. 2 Company Quick Takes: Merck, Immunovant, PureTech-Ariya, Viscient-Organovo and Durect

China approves Keytruda monotherapy for 1L NSCLC  China's National Medical Products Administration approved PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) as a monotherapy for first-line treatment of locally advanced or metastatic non-small...
BC Extra | Sep 10, 2019
Financial News

Sept. 10 Financial Quick Takes: Qiming backs Insilico's B round; plus 10x Genomics, Aprea, Platelet, SGI-DNA, Dermavant, Karuna Labs

Qiming leads Insilico’s $37M B round  Insilico Medicine Inc. (Hong Kong, China) raised $37 million in a series B round led by Qiming Venture Partners. Eight Roads, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu...
BC Extra | Sep 6, 2019
Company News

Sumitomo Dainippon to bolster pipeline via deal for women's health, urology, rare disease vants for $3B

Sumitomo Dainippon will pay $3 billion to acquire Roivant's stakes’ in five of its “vants” encompassing women's health, urology and rare diseases, propping up its pipeline as it anticipates losing U.S. market exclusivity on antipsychotic...
BC Extra | Aug 13, 2019
Company News

Management tracks: Chouraqui leaving Novartis; plus iTeos, Immunovant, Biodesix

Fabrice Chouraqui will step down as president of Novartis Pharmaceuticals U.S. at the end of August. Novartis AG (NYSE:NVS; SIX:NOVN) said he will be succeeded by 14-year Novartis veteran Victor Bulto, who is VP and...
Items per page:
1 - 10 of 116
BioCentury | Jul 24, 2020
Politics, Policy & Law

Moderna says commercial path remains clear despite unfavorable patent ruling

Moderna isn’t aware of any IP barriers to its products, including its COVID-19 vaccine, after a PTAB decision on Thursday shaved more than $3 billion off its market cap. The Patent Trial and Appeal Board...
BioCentury | Mar 19, 2020
Product Development

Roivant pivots towards ARDS in COVID-19; plus Italian studies of repurposed anti-inflammatories, vaccine updates and more

Wednesday saw a full slate of clinical updates across the globe for vaccine and therapeutic candidates to address COVID-19, while HHS launched a new public-private partnership to ramp up emergency drug packaging capabilities. Roivant Sciences...
BC Extra | Jan 25, 2020
Company News

Management tracks: Galapagos promotes Manto to CCO; plus Guardant, Horizon, Acceleron, Lilly, Krystal, Kura and more

Galapagos N.V. (Euronext:GLPG; NASDAQ:GLPG) promoted Michele Manto to chief commercial officer from SVP, commercial operations. Before joining the inflammation and fibrosis company in 2017, he was general manager, global marketing rheumatology at AbbVie Inc. (NYSE:ABBV)....
BC Extra | Jan 16, 2020
Company News

Jan. 15 Company Quick Takes: Japan Tobacco gets rights to Dermavant therapy; plus Clovis, BMS, Recordati, BeiGene, Insilico-Pfizer, Novartis

Japan Tobacco gets Japanese rights to Dermavant’s dermatology therapy  Japan Tobacco Inc. (TOKYO:2914) licensed from Dermavant Sciences exclusive rights to develop and commercialize tapinarof in Japan for dermatology indications including psoriasis and atopic dermatitis. The...
BC Extra | Nov 19, 2019
Clinical News

Big gain for Myovant as oral prostate cancer therapy heads for submission

Myovant shares more than doubled in value Tuesday after the company revealed Phase III data showing its oral GnRH receptor antagonist relugolix led to sustained testosterone suppression in 96.7% of prostate cancer patients in Phase...
BC Extra | Oct 31, 2019
Company News

Roivant pockets $3B from Dainippon, reveals CF focus of fifth ‘vant’

As Roivant cements its deal for Dainippon to acquire five of its “vants” for $3 billion, the biotech revealed the identity of the deal’s fifth subsidiary, which will develop gene therapies for cystic fibrosis. Sumitomo...
BC Extra | Oct 3, 2019
Company News

Oct. 2 Company Quick Takes: Merck, Immunovant, PureTech-Ariya, Viscient-Organovo and Durect

China approves Keytruda monotherapy for 1L NSCLC  China's National Medical Products Administration approved PD-1 inhibitor Keytruda pembrolizumab from Merck & Co. Inc. (NYSE:MRK) as a monotherapy for first-line treatment of locally advanced or metastatic non-small...
BC Extra | Sep 10, 2019
Financial News

Sept. 10 Financial Quick Takes: Qiming backs Insilico's B round; plus 10x Genomics, Aprea, Platelet, SGI-DNA, Dermavant, Karuna Labs

Qiming leads Insilico’s $37M B round  Insilico Medicine Inc. (Hong Kong, China) raised $37 million in a series B round led by Qiming Venture Partners. Eight Roads, F-Prime Capital, Lilly Asia Ventures, Sinovation Ventures, Baidu...
BC Extra | Sep 6, 2019
Company News

Sumitomo Dainippon to bolster pipeline via deal for women's health, urology, rare disease vants for $3B

Sumitomo Dainippon will pay $3 billion to acquire Roivant's stakes’ in five of its “vants” encompassing women's health, urology and rare diseases, propping up its pipeline as it anticipates losing U.S. market exclusivity on antipsychotic...
BC Extra | Aug 13, 2019
Company News

Management tracks: Chouraqui leaving Novartis; plus iTeos, Immunovant, Biodesix

Fabrice Chouraqui will step down as president of Novartis Pharmaceuticals U.S. at the end of August. Novartis AG (NYSE:NVS; SIX:NOVN) said he will be succeeded by 14-year Novartis veteran Victor Bulto, who is VP and...
Items per page:
1 - 10 of 116